Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?
- DOI
- 10.1016/j.bioorg.2026.109546
- Published
- 2026 May
- Container
- Bioorganic chemistry
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bioorg.2026.109546,
title = {Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?},
author = {Wang YL and Nie WZ and Lu FZ and Liu JY and He JH and Li YM and Li X and Shen QK},
year = {2026},
journal = {Bioorganic chemistry},
doi = {10.1016/j.bioorg.2026.109546},
url = {https://doi.org/10.1016/j.bioorg.2026.109546}
}RIS
TY - JOUR TI - Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors? AU - Wang YL AU - Nie WZ AU - Lu FZ AU - Liu JY AU - He JH AU - Li YM AU - Li X AU - Shen QK PY - 2026 JO - Bioorganic chemistry DO - 10.1016/j.bioorg.2026.109546 UR - https://doi.org/10.1016/j.bioorg.2026.109546 ER -
APA
YL, W., WZ, N., FZ, L., JY, L., JH, H., YM, L., X, L., & QK, S. (2026). Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?. Bioorganic chemistry. https://doi.org/10.1016/j.bioorg.2026.109546
Source records
- pubmed · retrieved 2026-09-26T19:13:01.354Z